Thus, the glucocorticoid receptor is a double-edged sword in prostate cancer. Due to it promoting the development of drug resistance in prostate cancer, it was shown to have oncogenic effects.

T-cell glucocorticoid receptor-deficient mice were generated using Lck promoter-driven, Cre recombinase-mediated excision of exon 2 of the glucocorticoid receptor gene.

Glucocorticoid Receptor Biology And Therapeutics Publication Trend. The graph below shows the total number of publications each year in Glucocorticoid Receptor Biology And Therapeutics.

Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist 92 targeting the AR ligand-binding pocket, but ...

The types of teeth are incisors, canines, premolars, and molars, and each serves a different purpose. Learn more about the types of teeth in this article.

US biotech Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced a strategic in-licensing agreement with China’s Hansoh Pharmaceuticals (03692: HK) for exclusive clinical development and ...

TARRYTOWN, N.Y., June 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced interim results from the ongoing Phase 2 COURAGE trial investigating novel ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a prostate, testicular, and penile cancers ...